Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Dec 20
Have your own idea? Try our Stock Screener
French (CAC) Biotech Industry Analysis
UpdatedDec 21, 2024
DataAggregated Company Financials
Companies26
- 7D-2.5%
- 3M-19.0%
- 1Y-30.5%
- YTD-31.3%
Over the last 7 days, the Biotech industry has dropped 2.5%, and Adocia contributed the most with a 19% decline. In contrast, Valneva has gained 5.1%. Overall the industry is down 31% in 12 months. Looking forward, earnings are forecast to grow by 5.4% annually.
Industry Valuation and Performance
Has the French Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 21 Dec 2024 | €2.3b | €654.7m | -€549,763,446.36 | 17.6x | -4.1x | 3.5x |
| Mon, 18 Nov 2024 | €2.5b | €654.6m | -€545,152,944.52 | 18.1x | -4.6x | 3.9x |
| Wed, 16 Oct 2024 | €2.7b | €627.6m | -€512,068,697.21 | 19.5x | -5.3x | 4.3x |
| Fri, 13 Sep 2024 | €3.0b | €525.1m | -€610,002,375.53 | 36.3x | -4.9x | 5.7x |
| Sun, 11 Aug 2024 | €3.0b | €517.2m | -€592,041,744.40 | 37x | -5x | 5.7x |
| Tue, 09 Jul 2024 | €2.9b | €511.8m | -€567,006,124.68 | 26.9x | -5.2x | 5.7x |
| Thu, 06 Jun 2024 | €3.4b | €509.6m | -€564,051,021.88 | 27.9x | -6x | 6.6x |
| Sat, 04 May 2024 | €3.2b | €503.5m | -€661,036,205.47 | 27.4x | -4.8x | 6.4x |
| Mon, 01 Apr 2024 | €3.2b | €501.1m | -€565,863,629.05 | 21.8x | -5.6x | 6.3x |
| Wed, 28 Feb 2024 | €3.2b | €558.7m | -€673,845,757.17 | 21.8x | -4.7x | 5.6x |
| Fri, 26 Jan 2024 | €3.1b | €594.6m | -€685,069,862.00 | 21.8x | -4.5x | 5.2x |
| Sun, 24 Dec 2023 | €3.2b | €594.1m | -€682,066,929.00 | 23x | -4.7x | 5.4x |
| Tue, 21 Nov 2023 | €3.4b | €594.1m | -€682,775,373.00 | 21.7x | -4.9x | 5.7x |
| Thu, 19 Oct 2023 | €3.3b | €806.5m | -€616,633,716.00 | 20.4x | -5.3x | 4.1x |
| Sat, 16 Sep 2023 | €3.9b | €818.2m | -€729,216,139.00 | 23.8x | -5.3x | 4.7x |
| Mon, 14 Aug 2023 | €3.7b | €817.7m | -€724,994,707.00 | 24.3x | -5.2x | 4.6x |
| Wed, 12 Jul 2023 | €3.7b | €818.4m | -€735,890,886.00 | 25x | -5x | 4.5x |
| Fri, 09 Jun 2023 | €3.7b | €820.5m | -€743,772,629.00 | 25.3x | -5x | 4.5x |
| Sun, 07 May 2023 | €3.6b | €831.1m | -€780,421,225.00 | 28.5x | -4.6x | 4.4x |
| Tue, 04 Apr 2023 | €3.2b | €960.9m | -€691,311,257.00 | 16.5x | -4.6x | 3.3x |
| Thu, 02 Mar 2023 | €3.6b | €1.0b | -€457,385,340.00 | 10.3x | -7.8x | 3.4x |
| Sat, 28 Jan 2023 | €3.7b | €1.0b | -€455,483,327.00 | 12.1x | -8.1x | 3.6x |
| Mon, 26 Dec 2022 | €3.4b | €1.0b | -€456,299,012.00 | 12.3x | -7.5x | 3.3x |
| Wed, 23 Nov 2022 | €3.4b | €929.8m | -€691,009,668.00 | 15.6x | -4.9x | 3.7x |
| Fri, 21 Oct 2022 | €3.7b | €914.1m | -€719,052,048.00 | 16.3x | -5.1x | 4x |
| Sun, 18 Sep 2022 | €4.0b | €928.5m | -€700,005,105.00 | 118.2x | -5.8x | 4.3x |
| Tue, 16 Aug 2022 | €4.8b | €931.5m | -€748,193,673.00 | 121.1x | -6.5x | 5.2x |
| Thu, 14 Jul 2022 | €4.3b | €989.4m | -€689,008,669.00 | 122.6x | -6.3x | 4.4x |
| Sat, 11 Jun 2022 | €4.5b | €990.4m | -€692,811,839.00 | 130.5x | -6.5x | 4.6x |
| Mon, 09 May 2022 | €4.5b | €1.0b | -€618,260,095.00 | 3.4x | -7.2x | 4.4x |
| Wed, 06 Apr 2022 | €5.4b | €1.2b | -€562,965,926.00 | 17.7x | -9.6x | 4.6x |
| Fri, 04 Mar 2022 | €5.0b | €944.7m | -€678,066,166.00 | 17.4x | -7.4x | 5.3x |
| Sun, 30 Jan 2022 | €5.2b | €933.9m | -€679,259,943.00 | 2.9x | -7.7x | 5.6x |
| Tue, 28 Dec 2021 | €7.4b | €928.1m | -€679,579,834.00 | 3.9x | -10.9x | 8x |
Price to Earnings Ratio
-10.9x
Current Industry PE
- Investors are pessimistic on the French Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 4.8x is higher than the industry's current PS ratio of 3.5x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 11% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the French Healthcare industry?
| FR Market | -1.72% | |
| Healthcare | 0.51% | |
| Biotech | -2.53% | |
| Biotech | -2.53% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| VLA Valneva | €1.92 | 5.1% +€15.1m | -57.7% | PS2x | |
| IPH Innate Pharma | €1.92 | 1.3% +€1.9m | -22.3% | PS4.6x | |
| ALCOX Nicox | €0.29 | 5.0% +€962.4k | -27.9% | PS4.3x | |
| ALVAL Valbiotis | €1.35 | 3.1% +€630.5k | -71.1% | PS40.4x | |
| ALVIO Valerio Therapeutics Société anonyme | €0.076 | 2.6% +€292.5k | -54.4% | PS6.2x |